| schema:articleBody
| - Imricor Medical Systems, Inc. (Companyor Imricor) (ASX:IMR) the worldwide leader in MRI-guided cardiac ablation products, is pleased to announce the first sales collaboration with Philips, a global leader in healthcare technology. This press release features multimedia. View the full release here: Imricor announces first sales partnership with Philips. (Photo: Business Wire) The sales collaboration provides Philips non-exclusive rights to re-sell Imricor's Advantage-MR System, along with Philips' industry-leading MRI scanners in European countries that recognize the CE mark. This agreement is the first such agreement signed by Imricor. Imricor's Chair and CEO, Steve Wedan said: "This agreement is a major milestone for Imricor, allowing Philips to take the lead on driving iCMR lab adoption and enabling us to focus on supporting utilization, growing our portfolio of consumable devices and expanding our indications for use. In this way, we each leverage our strengths as we work together to deliver a new standard of care in the treatment of cardiac arrhythmias." The Imricor products are specifically designed to enable cardiac ablations under real-time MRI guidance. Imricor is the first and only company to offer a fully MR conditional EP recorder/stimulator system and cardiac ablation catheters for use in the MRI environment. "Treatment procedures guided by MR represent an emerging field that extends the value of MR and complements established X-ray-based image-guided therapy systems," said Arjen Radder, General Manager MR Business at Philips. "By working with Imricor we can support healthcare providers to offer MRI-guided cardiac ablation procedures for their patients." This collaboration is the latest achievement in the partnership between Imricor and Philips, which began in 2010. "We are very proud to have a sales partnership with a company like Philips. We look forward to working with the talented Philips sales teams to leverage the extensive and outstanding relationships they have with customers, to help build new iCMR suites, and to identify potential customers that already have access to 1.5T compatible MRI systems." Greg Englehardt, Director of Sales at Imricor. About Imricor Please visit for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements. View source version on businesswire.com: Contact Investors: Steve Wedan Executive Chair, President and CEO Email: steve.wedan@imricor.com Carrie Barrack Senior Advisor, Cato & Clive Email: carrie@catoandclive.com Phone: +61 422 464 028 Rest of World Media: Nick Twohy Director of Marketing, Imricor Email: nick.twohy@imricor.com Phone: +1 952 818 8407 Australia Media: Carrie Barrack Senior Advisor, Cato & Clive Email: carrie@catoandclive.com Mobile: +61 422 464 028 © 2020 Business Wire, Inc. Disclaimer: This material is not an AFP editorial material, and AFP shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)